



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PTO FORM 1449**

ATTY. DOCKET NO.
11245/4740

SERIAL NO.
10/661,881

APPLICANT:
WAKSAL t al.

FILING DATE
September 11, 2003

GROUP
1642

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
ALH	4,943,533	July 1990	Mendelsohn			
	5,891,996	April 1999	Mateo de Acosta del Rio			
	5,558,864	September 1996	Bending			
	4,510,924		Gray			
	4,763,642		Horowitz			
	4,846,782		Bonnem			
	5,656,655		Spada et al.			
	5,646,153		Spada et al.			
	5,679,683		Bridges et al.			
	5,616,582		Barker			
	5,196,446		Levitzki et al.			
	5,736,534	April 1998	Arnold			
	*5,707,632		Williams et al.			
	*4,816,397					
	*4,816,567					
	*5,225,539					
	*5,658,570					
	*5,693,780					

*Copy of reference enclosed

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
ALH	WO 96/40210	December 19, 1996	PCT				
	*EP 502 812						
	*WO 93/21319						
	*EP 239 400						
	*WO 89/09622						
	*EP 338 745						
	*EP 331 424						

*Copy of reference enclosed.

/Anne Holleran/ (06/22/2006)

OTHER DOCUMENT

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
ALH		Goldkorn et al., "EGF receptor phosphorylation is affected by ionizing radiation", Biochimica et Biophysica Acta 1358, 1997, pp. 289-299
		Saleh et al., "Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation", Cancer Biotherapy & Radiopharmaceuticals, Vol. 14, No. 6, 1999, pp. 451-463
		Buehsbaum, D. et al., "In vitro and in vivo evaluation of the cytotoxicity of radiation combined with chimeric monoclonal antibody to the epidermal growth factor receptor," Proceeding of the American Association for Cancer Research, Vol. 37, March 1996 #4197. <i>duplicate citation</i>
		Chi Liu and Ming-Sound Tsao, "In Vitro and in Vivo Expression of Transforming Growth Factor- α and Tyrosine Kinase Receptors in Human Non-Small-Cell Lung Carcinomas," American Journal of Pathology, Vol. 142, No. 4, Apr. 1993, pp. 1155-1162
		Balaban, et al., Biochim. et Biophysica Acta 1314, 147-156 (1996)
		Snelling, Hybridoma 14, 111-114 (1995)
		Bender et al., Hybridoma 14, 129-134 (1995)
		Brady et al., Journal of Neurosurgical Sciences 34, 243-249 (1990)
		Brady et al., Int. J. Radiation Oncology Biol. Phys. 22, 225-230 (1992)
		Bender et al., Anticancer Research 17, 1797-1802 (1997)
		Saleh et al., Abstract 4197 in Proceedings of the American Association for Cancer Research, 37, 612 (1996)
		Dobelbower, Int. J. Radiation Oncology Biol. Phys. 39, 31-37 (1997)
		Lattanzi et al., Int. J. Radiation Oncology Biol. Phys., 38, 569-573 (1997)
		Willem et al., Ophthalmology 104, 1475-1479 (1997)
		Prewett et al., Journal of Immunotherapy 19, 419-427 (1997)
		Baselga et al., Journal of the National Cancer Institute 85, 1327-1333 (1993)
		Ciardiello et al., Clinical Cancer Research 1, 161-167 (1995)
		Ennis, Molecular Endocrinology 3, 1830-1838 (1989)
		Fry et al., Science 262, 1093-1095 (1994)
		Osharov et al., Journal of Biological Chemistry 268, 11134-11142
		Batley et al., Life Sciences 62, 143-150 (1998)
		Panek et al., Journal of Pharmacology and Experimental Therapeutics 1433-1444
		Parrizas et al., Endocrinology 138, 1427-1433 (1997)
		Osband et al., Problems in the Investigational Study and Clinical use of cancer immunotherapy, Immunotherapy, pp. 193-195
		*Masui et al., Cancer Res. 44, 5592-5598 (1986)
		*Aboud-Pirak et al., Journal of the National Cancer Institute 80, 1605-1611 (1998)
		*Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85, 2444-2448 (1998)
		*Kohler and Milstein in Nature 256, 495-497 (1975)
		*Burdon et al., Eds, Laboratory techniques in Biochemistry and molecular Biology, Vol. 13, Elsevier Science Publishers, Amsterdam (1985)
		*Co et al., Nature 351, 501-502 (1992)
		*Queen et al., Proc. Natl. Acad. Sci. 86, 10029-1003 (1989)
		*Rodriguez et al., Int. J. Cancer, Supplement 7, 45-50 (1992)

*Copy of reference enclosed.

/Anne Holleran/ (06/22/2006)

EXAMINER	/Anne Holleran/ (06/22/2006)	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		